Schedule 13G ownership disclosure
KINIKSA PHARMACEUTICALS INTL
Class A Ordinary Shares, nominal value $0.000273235 per share · CUSIP: G52694109
Event date: 2025-03-28
Reporting persons may disclose overlapping interests. Their amounts are shown individually and are not added into a filing total.
- Filing-level shares
- Unavailable
- Percent of class
- Unavailable
- TANG CAPITAL MANAGEMENT, LLC
Shares: 2,178,609.00 · Class: 5.2%
- KEVIN TANG
Shares: 2,178,609.00 · Class: 5.2%
- TANG CAPITAL PARTNERS, LP
Shares: 1,041,271.00 · Class: 2.5%
- TANG CAPITAL PARTNERS INTERNATIONAL, LP
Shares: 953,337.00 · Class: 2.3%
- TANG CAPITAL PARTNERS III, INC
Shares: 139,379.00 · Class: 0.3%
- TANG CAPITAL PARTNERS IV, INC
Shares: 44,622.00 · Class: 0.1%
Amounts are as disclosed in this filing. Schedule type alone does not establish investment intent.
Source: SEC EDGAR filingFiling metadata
- Accession number
- 0001214659-25-005483
- Form type
- SCHEDULE 13G
- Filer
- Kiniksa Pharmaceuticals International, plc
- CIK
- CIK 1730430
- Filed
- Apr 04, 2025
- Reporting period
- Mar 28, 2025
- Description
- Schedule 13G beneficial ownership